NIH High-Risk, High-Reward Research Programs
NIH has four high-risk, high-reward research programs. Research may be basic, translational, or clinical. The primary requirements
are that the research be highly innovative and have the potential for unusually broad impact. None of these programs requires
preliminary data or a detailed experimental plan. What is required a great idea and compelling logic of how it might be achieved.
The Pioneer Award Program: for investigators at any career stage who have a record of unusually innovative research and who
propose pioneering ideas going forward. (Application receipt date of September 11, 2020.)
The New Innovator Award: for Early Stage Investigators (those within ten years of receipt of their terminal research degree or
completion of their clinical training) who propose unusually innovative and impactful research. (Application receipt date of
August 21, 2020.)
The Transformative Research Awards: for individuals (single Principal Investigator) or teams (multiple Principal Investigators)
who propose unconventional, potentially groundbreaking research projects with flexible budgets. (Application receipt date of
September 30, 2020.)
The Early Independence Awards: for exceptional junior scientists who wish to “skip the post-doc” to launch independent research
careers (only up to two applications per institution are allowed). (Application receipt date of September 4, 2020.)
See attached flyer for additional information.
NIH Protecting U.S. Biomedical Intellectual Innovation: NIH and the biomedical research enterprise have a long history of
International collaborations with rules of engagement that allow science to advance while also protecting intellectual capital and proprietary
information of the participating countries. These rules of engagement also are designed to limit bias in the design, conduct, and reporting
of NIH-supported research. This website describes actions that NIH, institutions, and researchers can take to protect U.S. biomedical
intellectual innovation. For Examples of What to Disclose to NIH about Senior/Key Personnel on Applications and Awards please see the
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/Examples of What to Disclose to NIH about Senior.docx?ver=2020-07-20-071838-987
PRESBYTERIAN HEALTH FOUNDATION GRANTS – REQUEST FOR APPLICATIONS – CYCLE II BRIDGE
GRANT PROGRAM– DUE DATE AUGUST 21, 2020
The primary objective of the PHF Bridge Grant program is to provide funding to enhance OUHSC faculty competitiveness for
extramural funding. OUHSC Principal Investigators who have submitted an extramural application that was scored but not funded
within the past 18 months and is requesting over $750,000 in total direct costs and over $200,000 in total facilities and administration
(F&A) costs and received a review that ranks applications and provides critiques are eligible. This program can provide funding for
up to $75,000 for one year. Guidelines and Application Form is attached or can be found at:
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/PHF-Bridge Grant Guidelines - 07.06.2020.docx?ver=2020-07-13-101339-100
NIH Posts COVID-19 Guidance for Preparing Fall 2020 Applications
The NIH Office of the Director’s released new guidance for preparing grant applications with fall 2020 due dates, the earliest being
Sept. 25. The guidance states that NIH grant applications should not include COVID-19 contingency plans and that reviewers will be
instructed to disregard situations due to COVID-19. For additional information go to:
OCAST – the Health Research Proposal board does not meet until August 11, 2020. We will not know anything about who will be
funded until after August 11th.
The Stephenson Cancer Center is pleased to announce the American Cancer Society – Institutional Research Grant
(ACS-IRG) Pilot Project grant funded by the American Cancer Society. The ACS-IRG is a unique source of funding entrusted to
SCC that provides seed money for young investigators interested in cancer-related research. While the grant is administered at SCC,
eligible applicants at OUHSC Tulsa, OU Norman and OU-Tulsa may apply.
Applicants may request up to $50,000 for a 12-month project that:
- Is relevant to the goals of the ACS and is cancer-related
- Has high scientific merit
- Has potential to be leveraged for future extramural funding
Only full time Assistant Professors within six years of their initial faculty appointment and with no active peer-reviewed funding from
national funding agencies (e.g. NIH, DOD, NSF, ACS) may apply. Applications must be received by the Office of Cancer Research
(email@example.com) by 5 PM, September 8th, 2020. Application guidelines and application packet are attached.
Interested applicants can discuss their proposal, eligibility, allowable budget items, and available funding by contacting the Office of
Cancer Research staff at firstname.lastname@example.org or call 405-271-1878.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/ACS-IRG Guidelines-Fall-2020.pdf?ver=2020-07-13-101339-037
NEW CITI Course: COVID-19: Back to Campus
AAMC and CITI Program have partnered to launch a complimentary course for staff, students, and faculty on safely returning to research
activities on campus. This course is strictly voluntary for those wishing to have additional information about how to maintain a safe
research environment in the time of COVID-19. This course was designed by AAMC and CITI and does not necessarily follow all of
OUHSC guidelines for return to work or return to research (which can be found here:
https://research.ouhsc.edu/Resources/COVID-Research-Updates). Please be certain to review OUHSC policies if you have any questions.
You can access the course by following the instructions attached.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/CITI Instructions for New COVID-19 Course.docx?ver=2020-07-06-081424-413
OMB M-20-26: Extension of Administrative Relief for Recipients and Applicants of Federal Financial Assistance
(COVID-19) - a memo was published by OMB, extending certain of the flexibilities provided by M-20-17.
NIH WILL ACCEPT PRELIMINARY DATA AS POST-SUBMISSION MATERIAL AND OTHER COVID-19 RELATED
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website
(http://octsi.ouhsc.edu/covid-19%20working%20group) A list of investigators in the working group and their planned or ongoing projects are
described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma Covid-19
Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation Presidential Professor,
Department of Microbiology and Immunology, OUHSC ( email@example.com ).
Oklahoma Shared Clinical and Translational Resources Clinical and Translational Research Pilot (CTRP) Grants
The purpose of the program is to provide funding for collaborative and/or multi-disciplinary clinical and translational pilot projects between
investigators of the OSCTR member institutions. The program seeks to support proposals designed to generate preliminary data that will
result in improved health and/or healthcare for citizens of Oklahoma and other IDeA states and enhance the competitiveness of the investigators
for future extramural funding. The program also seeks to fund innovative concepts, approaches, and methodologies that bring fresh new ideas
to solving the health issues of those living in Oklahoma and collaborating IDeA states. Projects that focus on the medically underserved and on
health concerns prevalent within Oklahoma and our OSCTR partners will be a priority. Only projects which meet the NIH definition of clinical
and/or translational research will be accepted.
Approved CTRP grants will be funded for a period starting January 1, 2021 contingent on NIH approval of just in time (JIT) information.
All funds are required to be expended by December 31, 2021.
The forms, instructions, and submission link can be found at: http://osctr.ouhsc.edu/pilots2020
Deadlines for submission: Pilot Proposal – Friday, August 7, 2020 at 5:00 PM CDT
Oklahoma Shared Clinical and Translational Resources Community-Engaged Research Exploratory (CERE) Awards
This program is intended to support community engagement to develop funded research partnerships. Funds can be used for research
development activities, including convening partners, working with individuals pursuing related work, and conducting needs assessments
in community settings. The funds cannot be used to support actual human-subjects research protocols, which can be funded under other
OSCTR pilot research programs and/or external funding.
The application should consist of a 2-page letter from the main applicant (which can be either a community agency or an academic researcher)
describing the collaboration, the contributions that the proposed work will make to a successful research partnership, and a line item budget.
Budget requests are expected to be $5,000-$10,000 with budgets that permit the expenditure of the entire award by June 30, 2021.
A separate letter of support from either the academic or community partner indicating their agreement with the proposed activities should
also be included. Proposals will be evaluated on a rolling basis beginning July 1, 2020. Please submit proposals by email to firstname.lastname@example.org.
Interested applicants can discuss their proposal, eligibility, allowable budget items, and available funding by contacting the OSCTR staff at
email@example.com or call 405-271-3480.
OU Office of Technology Commercialization presents a new opportunity to engage with industry (email firstname.lastname@example.org or
email@example.com for specific submission details):
Provepharm Life Solutions is looking to engage with academia for developing novel small molecule-peptide conjugates with therapeutic
benefits (OUT OF SCOPE: antibody-drug conjugates, highly potent conjugates). Non-confidential summary application (200-300 word
abstract) due August 3rd, 2020.
- Optimizing aspects relating to the conjugation of small molecules and peptides
- Optimization to enhance overall functionality of small molecule-peptide conjugates
- Fluorescence-guided surgery for immuno-oncology
The OU Medicine Laboratory is looking for equipment to assist with their COVID-19 testing. Please see the attached list
of equipment needs. Please reply to VPR@ouhsc.edu if you have any of this equipment you could possibly loan.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/COVID Ramp Up Ask List.docx?ver=2020-06-01-083246-413
DONATION OF TESTING SUPPLIES
OU Physicians has requested that researchers look into their supplies and see whether they can donate any of the Testing supplies listed
in the attached “Testing Donations”. Please return the complete form to Kristen.Namey@oumedicine.com.
DONATION OF PPE SUPPLIES
OU Physicians has requested that researchers look into their supplies and see whether they can donate any of the PPE supplies listed
in the attached “research PPE donation”. The first line is an example of how to fill out the form. Please return completed form to
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/Copy of research PPE donation.xlsx?ver=2020-06-01-083245-163
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
Fast-Grants – Fast Funding for COVID-19 Science
NIH has created a central site for its current COVID-19 guidance at
OUHSC Financial Administrators:
The federal and state governments are asking that all institutions track their expenditures related to the COVID-19
pandemic. It is imperative that everyone is diligent in tracking all COVID-19 related expenditures for future reimbursement opportunities.
Effective immediately, all COVID-19-related expenditures incurred since March 12 should be coded to a newly created COVID subclass.
These expenditures include, but are not limited to direct COVID-19 costs, increased housekeeping and maintenance costs, expenditures
related to business process modifications, preparatory actions, daily operations, and communications resulting from COVID-19. If COVID
related expenses, since March 12, have already been paid, please process a cost transfer using the new COVID subclass. Research faculty
and staff should also track their expenditures incurred by the shutdown of their projects and laboratories including the loss of samples,
reagents, animals and other items. Also, keep in mind that, asyou resume your activities in your lab, any expenses required to restart the
lab should be coded with the COVID subclass. This will help significantly when applying for any administrative supplements or other
COVID-19 related relief efforts. Questions regarding the use of the subclass on non-research chartfields should be forwarded to
firstname.lastname@example.org and research related questions can be sent to email@example.com.
OUHSC Funding Requests related to COVID-19 – when submitting an item in the OUHSC SoonerTrack system related to COVID-19
please include “COVID-19” in the title so that we are able to search on it later.
COVID-19/Coronavirus Resources – a list from InfoEd
Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus
Disease 2019 (COV-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
Notice of Early Expiration of "Notice of Special Interest (NOSI) Regarding the Availability of Emergency Competitive Revisions for Research
on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-058)
Notice Announcing the National Institute of Mental Health (NIMH) Expectations for Collection of Common Data Elements (NOT-MH-20-067)
Guidance for Applicants Preparing Applications for the Fall 2020 Due Dates During the COVID-19 Pandemic (NOT-OD-20-122)
Request for Information (RFI): Seeking Stakeholder Input on Scientific Gaps and Research Needs Related to Delivery of Cancer-Related Care
via Telehealth (NOT-CA-20-080)
Notice to Extend the Expiration Date for PAR-17-287 "NIA Academic Leadership Career Award (K07)"
Notice of NIAMS Participation in PA-20-135, "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial
Notice of Participation of NCCIH in PAR-19-342, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC)
Institutionally-Focused Research Education Award to Promote Diversity (UE5 - Clinical Trial Not Allowed)" (NOT-AT-20-018)
Notice of Participation of NCCIH in PAR-19-343, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC)
Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)" (NOT-AT-20-019)
Notice of Clarification to Key Dates for RFA-CA-20-039 "Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences
(U01 Clinical Trial Optional)" (NOT-CA-20-076)
Notice of Changes to the Dates in the Final Receipt, Review, Council, and Award Cycle and to the Expiration Date of PAR-19-101,
"Physical Sciences-Oncology Network (PS-ON): Physical Sciences-Oncology Projects (PS-OP) (U01 Clinical Trial Optional)" (NOT-CA-20-084)
Notice to Add a Receipt Date to RFA-DA-21-019 Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion:
CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed) (NOT-DA-20-063)
Notice of Change to Application Receipt Dates and Clarification of Eligibility Information for PAR-20-220, Institutional Network Award for
Promoting Kidney, Urologic, and Hematologic Research Training (U2C-Clinical Trial Not Allowed) (NOT-DK-20-038)
Notice of Change to Instructions for Human Subjects and Clinical Trial Information in PAR-19-312 Limited Competition: Renewal of
Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 Clinical Trial Optional)" (NOT-GM-20-035)
Notice of Change to Instructions for Human Subjects and Clinical Trial Information in PAR-19-313 "Centers of Biomedical Research
Excellence (COBRE) Phase 1 (P20 Clinical Trial Optional)
Notice to Extend Response Date for NOT-GM-20-034: "Request for Information: Soliciting Input on the NIGMS 2021-2025 Strategic
Plan Framework" (NOT-GM-20-044)
Notice of Additional Eligibility Information in PAR-20-100 Genomic Community Resources (U24)
Notice of Participation in PA-18-358, "NINDS Exploratory Neuroscience Research Grant (R21- Clinical Trial Optional)" (NOT-MH-20-034)
Notice of New Budget Limitation for PAR-18-657 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence
(U54 Clinical Trial Optional)" (NOT-NS-20-085)
Notice of Change to Key Dates for PAR-18-657 "Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence
(U54 Clinical Trial Optional)".(NOT-NS-20-086)
Notice of Change to Key Dates for PAR-19-039 "Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead
Compounds (U01 Clinical Trial Not Allowed)"
Notice of Change to Key Dates for PAR-19-040 "Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead
Compounds (U01 Clinical Trial Optional)"
Notice of Clarification to Application Types Allowed PAR-20-111 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery
and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)" (NOT-NS-20-091)
Notice of Change to Key Dates for RFA-NS-20-030 "Research Program Award (R35 Clinical Trial Optional)" (NOT-NS-20-092)
Notice of Intent to Publish a Funding Opportunity Announcement for ALACRITY Centers for Practice-Based Effectiveness and Services
Research with Near-Term Impact (P50 Clinical Trial Optional)
Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-059)
Notice of Special Interest (NOSI): National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training
Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19) (NOT-CA-20-082)
Please Note: When only one application is allowed per Institution according to the sponsor
instructions, a one-page letter of intent summarizing the proposed project should be submitted
to the Vice President for Research at least two months prior to the application deadline (unless
otherwise noted). The letters of intent will be reviewed and a single application will be chosen
for submission from the University.
Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related
Research (Parent F31-Diversity) (PA-20-251) – Deadline August 8, 2020 and December 8, 2020
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, Clinical Trial Not Allowed) (PAR-20-128)
Deadline September 5, 2020 and January 5, 2021
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development
(SB1, Clinical Trial Not Allowed) (PAR-20-129) – Deadline September 5, 2020 and January 5, 2021
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development
(SB1 Clinical Trial Required) (PAR-20-130) – Deadline September 5, 2020 and January 5, 2021
Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed)
(PAR-20-253) - Deadline May 26, 2021and May 31, 2022
Tobacco Use and HIV in Low and Middle-Income Countries (U01 Clinical Trial Optional) (RFA-CA-20-037) – Deadline September 24, 2020
Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) (RFA-DK-20-011)
Deadline November 4, 2020
Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
(RFA-DK-20-012) - Deadline November 4, 2020
Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK
(R01 Clinical Trial Optional) (RFA-DK-20-021) - Deadline December 16, 2020
Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical Trial Optional)
(RFA-FD-21-004) - Deadline October 14, 2020